Laurie McGinley

Washington, D.C.

Reporter covering health and medicine

Education: Syracuse University, BS in journalism

Laurie McGinley covers health and medicine for The Washington Post. She focuses on the Food and Drug Administration as well as cancer research and treatment. She was previously The Post's health, science and environment editor.
Share confidential news tips with The Post
Latest from Laurie McGinley

FDA orders Juul e-cigarettes off the market over safety concerns

The action is a major blow to the once high-flying Silicon Valley firm that revolutionized vaping.

June 23, 2022

Biden administration says it plans to cut nicotine in cigarettes

The FDA is expected to say it will work on a proposal to lower nicotine to minimally or nonaddictive levels.

June 21, 2022

FDA authorizes coronavirus vaccine for young kids with shots likely next week

For many parents and pediatricians, the Food and Drug Administration clearing of two vaccines comes as a huge relief.

June 17, 2022

FDA advisers back authorization of coronavirus vaccines for tots

Food and Drug Administration officials could act on the recommendation within days, potentially setting the stage for shots to be available next week.

June 15, 2022

FDA advisers recommend Moderna shot for older children, adolescents

A greenlight from the FDA, followed by an endorsement by the Centers for Disease Control and Prevention, would give parents another choice of shots for school-age children and adolescents.

June 14, 2022

Pfizer-BioNTech shot for children under 5 safe and effective, FDA staff says

The finding could pave the way for vaccines for the youngest children this month.

June 12, 2022

FDA says Moderna vaccine for youngest children is safe and effective

The analysis sets the stage for a review by the agency’s outside advisers Wednesday and a potential authorization by the end of the week.

June 10, 2022

    Covid shots for young kids are almost available. Here’s what you need to know.

    If all goes as expected, two vaccines — one by Moderna, the other by Pfizer and its German partner, BioNTech — will be authorized by federal authorities and be available by June 21.

    June 10, 2022

    FDA advisers recommend authorizing Novavax coronavirus vaccine

    The Novavax vaccine is a protein vaccine, a more traditional technology found in other commonly used immunizations such as hepatitis B and influenza.

    June 7, 2022

    Pfizer covid shot 80 percent effective in younger kids, early data shows

    The data is a step toward a vaccine for infants, toddlers and children younger than 5 — the last age group to lack access to a coronavirus vaccine in the United States.

    May 23, 2022